Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 12;12(12):1708.
doi: 10.3390/brainsci12121708.

Serum Inflammatory Profile in Hereditary Transthyretin Amyloidosis: Mechanisms and Possible Therapeutic Implications

Affiliations

Serum Inflammatory Profile in Hereditary Transthyretin Amyloidosis: Mechanisms and Possible Therapeutic Implications

Marco Luigetti et al. Brain Sci. .

Abstract

Hereditary transthyretin (ATTRv) amyloidosis is a severe, progressive, and heterogeneous multisystemic condition due to mutations in the TTR gene. Although multiple aspects of its molecular pathophysiological mechanisms have been elucidated over the years, it is possible to hypothesize different pathogenetic pathways. Indeed, we extensively investigated the serum levels of several molecules involved in the immune response, in a cohort of ATTRv patients and healthy controls (HCs). Sixteen ATTRv patients and twenty-five HCs were included in the study. IFN-alpha levels were higher in ATTRv patients than in HCs, as well as IFN-gamma levels. By contrast, IL-7 levels were lower in ATTRv patients than in HCs. No significant difference between groups was found regarding IL-1Ra, IL-6, IL-2, IL-4, and IL-33 levels. Correlation analysis did not reveal any significant correlation between IFN-α, IFN-γ, IL-7, and demographic and clinical data. Larger and longitudinal studies using ultrasensitive methods to perform a full cytokine profiling are needed to better elucidate the role of inflammation in ATTRv pathogenesis and to test the reliability of these molecules as possible biomarkers in monitoring patients' progression.

Keywords: ATTRv; biomarker; degeneration; inflammation; therapy.

PubMed Disclaimer

Conflict of interest statement

Marco Luigetti received financial grants (honoraria and speaking) from Ackea, Alnylam, Sobi, and Pfizer, and travel grants from Ackea, Alnylam, Sobi, Pfizer, Kedrion, and Grifols; Angela Romano received financial grants (honoraria and speaking) from Akcea, and travel grants from Akcea, Alnylam, Pfizer, and Csl Behring. Nicola De Stefano: Unrelated to this work, NDS is a consultant for Merck, Novartis, Sanofi Genzyme, Roche, and Bristol Myers Squibb and is on the speakers’ bureaus of Merck, Novartis, Roche, Sanofi Genzyme, Janssen and Bristol Myers Squibb. He has received travel funds from Merck, Novartis, Roche, Sanofi-Genzyme, and Teva and has grants pending from FISM. He is co-founder of Siena Imaging. Guido Primiano, Andrea Sabino, Valeria Guglielmino, Maria Ausilia Sciarrone, Francesca Vitali, Geny Piro, Carmine Carbone have no potential conflicts of interest to be disclosed. Domenico Plantone: Unrelated to this work, DP has received travel funds from Lilly and Novartis. Marco Luigetti, Angela Romano, and Guido Primiano are members of the European Reference Network for Neuromuscular Diseases—Project ID N° 870177.

Similar articles

Cited by

References

    1. Adams D., Koike H., Slama M., Coelho T. Hereditary transthyretin amyloidosis: A model of medical progress for a fatal disease. Nat. Rev. Neurol. 2019;15:387–404. doi: 10.1038/s41582-019-0210-4. - DOI - PubMed
    1. Manganelli F., Fabrizi G.M., Luigetti M., Mandich P., Mazzeo A., Pareyson D. Hereditary Hereditary transthyretin amyloidosis overview. Neurol. Sci. 2020 doi: 10.1007/s10072-020-04889-2. Online ahead of print. - DOI - PMC - PubMed
    1. Sekijima Y. Transthyretin (ATTR) amyloidosis: Clinical spectrum, molecular pathogenesis and disease-modifying treatments. J. Neurol. Neurosurg. Psychiatry. 2015;86:1036–1043. doi: 10.1136/jnnp-2014-308724. - DOI - PubMed
    1. Ferraro P.M., D’Ambrosio V., Di Paolantonio A., Guglielmino V., Calabresi P., Sabatelli M., Luigetti M. Renal Involvement in Hereditary Transthyretin Amyloidosis: An Italian Single-Centre Experience. Brain Sci. 2021;11:980. doi: 10.3390/brainsci11080980. - DOI - PMC - PubMed
    1. Minnella A.M., Rissotto R., Maceroni M., Romano A., Fasciani R., Luigetti M., Sabatelli M., Rizzo S., Falsini B. Ocular Involvement in Hereditary Transthyretin Amyloidosis: A Case Series Describing Novel Potential Biomarkers. Genes. 2021;12:927. doi: 10.3390/genes12060927. - DOI - PMC - PubMed